Equity · Healthcare
NBP
NASDAQNovaBridge Biosciences (NBP)
The line runs 1.88 USD on 24 August through 1.30 USD on 13 October, on a scale from 1.2 to 2.0. Days the market did not trade hold the previous close, flat.
- EPS, diluted, year to Dec 2025
- −0.21 USD
- 52-week range
- 1.30 USD – 5 USD
- Avg volume
- 40.6K
as of Oct 13, 2026
Have NovaBridge Biosciences (NBP) insiders bought or sold shares recently?
In the 90 days to 22 Nov 2026, NovaBridge Biosciences insiders reported 3 open-market sales and 2 purchases (SEC Form 4).
Form 4, 90 days to 22 Nov 2026, newest reported trade 18 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 18 Nov 2026 | Hagler Mark ArnoldChief Commercial Officer | Buy | 184,000 | 70K USD |
| 17 Nov 2026 | Hagler Mark ArnoldChief Commercial Officer | Buy | 46,000 | 16K USD |
| 18 Sep 2026 | Dennis Phillip AndrewChief Medical Officer | Sell | 8,209 | 6K USD |
| 09 Sep 2026 | Cao Sean WuxiongChief Bus. Development Officer | Sell | 107,978 | 80K USD |
| 31 Aug 2026 | Xu Cong ClaireEVP, Clinical Development | Sell | 3,282 | 3K USD |
| Bought | 2 open-market purchases | 230,000 | $86K | |
| Sold | 3 open-market sales | 119,469 | $88K |
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 15 Oct 2026 | Woo Ian YingDirector | Option exercise | 13,271 | |
| 17 Sep 2026 | Dennis Phillip AndrewChief Medical Officer | Option exercise | 23,695 | |
| 03 Sep 2026 | Cao Sean WuxiongChief Bus. Development Officer | Option exercise | 339,372 | |
| 30 Aug 2026 | Xu Cong ClaireEVP, Clinical Development | Option exercise | 9,382 |
Which funds hold NovaBridge Biosciences (NBP)?
4 of the 45 institutional funds we track reported a NovaBridge Biosciences position for the quarter ended 30 Sep 2026 — a combined 4.7M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Citadel Advisors | Added | 1,381,516 | 1.9M USD | +121.8% |
| Two Sigma Investments | Held (±25%) | 874,250 | 1.2M USD | +2.7% |
| Marshall Wace | Trimmed | 727,345 | 989K USD | −41.0% |
| Renaissance Technologies | Trimmed | 485,191 | 662K USD | −36.0% |
What has been filed or recorded for NovaBridge Biosciences (NBP)?
The filings we hold for NovaBridge Biosciences, newest first: 3 fails-to-deliver days and 4 reported financial figures, the latest dated 30 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 44,124 shares | 53K USD notional · 0.017% of shares out |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 26,125 shares | 35K USD notional · 0.010% of shares out |
| 07 Oct 2026 | Fails to deliver | Shares failed to deliver | 100 shares | 140 USD notional · <0.001% of shares out |
| 31 Dec 2025 | Financials | Net income | −46.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −0.21 USD | fiscal year |
| 31 Dec 2025 | Financials | Total assets | 260.5M USD | at period end |
| 31 Dec 2025 | Financials | Total equity | 230.9M USD | at period end |
What do people ask about NovaBridge Biosciences (NBP)?
What did NovaBridge Biosciences shares close at?1.30
NovaBridge Biosciences closed at 1.30 USD on 13 Oct 2026, down 1.52% on the close before. That is the end-of-day price from Finazon, not a live quote.
Have NovaBridge Biosciences insiders bought or sold shares recently?3 sales
In the 90 days to 22 Nov 2026, NovaBridge Biosciences insiders reported 3 open-market sales and 2 purchases (SEC Form 4). A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own NovaBridge Biosciences?4 of 45
4 of the 45 funds we track reported a NovaBridge Biosciences position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Two Sigma Investments and Marshall Wace. See Funds

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 31 Dec 2025